Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 17, 2025Heart

Managing glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors in clinical practice

View Full Paper
Ask AI
Bookmark
Share

Authors

HDHermann DalpiazSMStefano MasiSPSara Piludu

Discussion

Loading...

Member takes

Overview

Review highlights GLP-1RAs and SGLT2is in improving outcomes for cardiovascular and kidney diseases, suggesting expanded clinical use.

Key Points

  • GLP-1 receptor agonists and SGLT2 inhibitors reduce the risk of cardiovascular and kidney diseases.
  • Randomised controlled trials show significant benefits of SGLT2is in heart failure patients.
  • Current guidelines advocate broader use of these medications across various clinical phenotypes.
  • Combination therapy of GLP-1RA and SGLT2i may optimize treatment for high cardiovascular risk patients.

Cite This Study

Dalpiaz et al. (2025) studied this question.

synapsesocial.com/papers/689a02c9e6551bb0af8cce1dhttps://doi.org/10.1136/heartjnl-2024-324847
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Combined use of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors for cardiovascular protection2026
  2. 2Repurposing Diabetes Therapies in CKD: Mechanistic Insights, Clinical Outcomes and Safety of SGLT2i and GLP-1 RAs2025 · 8 citations
  3. 3SGLT2 Inhibitors: Multifaceted Therapeutic Agents in Cardiometabolic and Renal Diseases2025 · 15 citations
  4. 4SGLT2 Inhibitors and GLP-1 Receptor Agonists in Cardiovascular–Kidney–Metabolic Syndrome2025
  5. 5Efficacy of Dual Glucagon and Glucagon-like Peptide-1 Receptor Agonists Across the Cardiometabolic Continuum: A Review of Current Clinical Evidence2025